

PHARMACOLOGY
BIOCHEMISTRY
AND
BEHAVIOR

VOLUME 46, 1993
SUBJECT AND AUTHOR INDEX



Pergamon Press
New York • Oxford • Seoul • Tokyo

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editor-in-Chief

MATTHEW J. WAYNER

Division of Life Sciences, The University of Texas at San Antonio, San Antonio, TX 78249-0662

European Editor-in-Chief

SANDRA E. FILE

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK

Editorial Advisory Board

- | | |
|---|--|
| L. AHTEE, Helsinki, Finland | GEORGE F. KOOB, La Jolla, CA |
| L. ALLIKMETS, Tartu, Estonia | CONAN KORNETSKY, Boston, MA |
| ROBERT L. BALSTER, Richmond, VA | J. DAVID LEANDER, Indianapolis, IN |
| G. BIGGIO, Cagliari, Italy | EMINY H. Y. LEE, Taipei, Taiwan |
| M. BRILEY, Castres, France | ALLEN S. LEVINE, Minneapolis, MN |
| ALLAN C. COLLINS, Boulder, CO | WILLIAM J. McBRIDE, Indianapolis, IN |
| DONALD V. COSCINA, Toronto, Ontario, Canada | DONALD E. McMILLAN, Little Rock, AR |
| JACQUELINE N. CRAWLEY, Bethesda, MD | JACK H. MENDELSON, Belmont, MA |
| A. DOMENEY, Bradford, UK | ROBERT D. MYERS, Greenville, NC |
| ADRIAN J. DUNN, Shreveport, LA | J. A. PRATT, Glasgow, UK |
| BURR EICHELMAN, Philadelphia, PA | ROSARIO SAMANIN, Milan, Italy |
| WILLIAM J. FREED, Washington, DC | HERMAN H. SAMSON, Winston-Salem, NC |
| RICHARD A. GLENNON, Richmond, VA | PAUL R. SANBERG, Tampa, FL |
| F. G. GRAEFF, São Paulo, Brazil | PHIL J. SKOLNICK, Bethesda, MD |
| M. R. C. GREENWOOD, Davis, CA | S. C. STANFORD, London, UK |
| ROLAND R. GRIFFITHS, Baltimore, MD | M.-H. THIÉBOT, Paris, France |
| STEPHEN G. HOLTZMAN, Atlanta, GA | DEREK VAN DER KOOY, Toronto, Ontario, Canada |
| AKIRA HORITA, Seattle, WA | JEANNE M. WEHNER, Boulder, CO |
| CHRIS E. JOHANSON, Baltimore, MD | BRUNO E. WILL, Strasbourg, France |
| HAROLD KALANT, Toronto, Ontario, Canada | J. C. WINTER, Buffalo, NY |
| G. JEAN KANT, Washington, DC | ALICE M. YOUNG, Detroit, MI |
| KATHLEEN M. KANTAK, Boston, MA | IAN S. ZAGON, Hershey, PA |
-

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

US Editorial Office:

Matthew J. Wayner

Division of Life Sciences, The University of Texas at San Antonio, 6900 North Loop 1604 West
San Antonio, TX 78249-0662
Fax: (210) 691-4510

European Editorial Office:

Sandra E. File

Psychopharmacology Research Unit, UMDS Division of Pharmacology, Guy's Hospital
P.O. Box 3448, London SE1 9QH, UK
Fax: 44-(0)71-955-4627

Production Editor:

Jonathan R. Goodnough

Pergamon Press, Tarrytown, NY 10591-5153

Publishing, Subscription, and Advertising Offices:

Pergamon Press Inc., 660 White Plains Road, Tarrytown, NY 10591-5153, USA, E-mail Address:
ESUK.USA@ELSEVIER.COM; and Pergamon Press Ltd., Headington Hill Hall, Oxford OX3 0BW, UK

Published Monthly

Annual institutional subscription rate (1993): £785 (US\$1256)

Sterling prices are definitive. US dollar prices are quoted for convenience only and are subject to exchange rate fluctuation. Prices include postage and insurance and are subject to change without notice.

SUBJECT INDEX

- Acetylcholinesterase activity, 729
ACTH, 101
Activity, 243
Adaptation, 445
Addiction, 125
Adenylate cyclase, 289, 519
Adrenal medulla, 225
Adrenergic, 251
Affective disorder, 243
Aggression, 923
Aging, 27, 101, 405, 415, 799
Agonist, 759
Agonistic behavior, 67, 873
Agoraphobia, 715
Agoraphobia (thigmotaxis), 973
AH 6809, 383
Alcohol, 463, 985
Alcohol drinking, 365, 751
Alcohol-nonpreferring rats, 173, 631, 723
Alcohol-preferring rats, 173, 631, 723
Alcohol self-administration, 35
Alcohol withdrawal, 365
Allotetrahydrodeoxycorticosterone, 963
 α -Adrenoceptors, 39
 α_2 -Adrenoceptor, 111
 α -Ethyltryptamine (α -ET), 459
 α -Lipoic acid, 799
 α -Methyltryptamine (α -MeT), 459
 α_2 -Receptor, 117
Alprazolam, 89, 167
Amiloride, 83
AMPA receptors, 73, 703
AMPA/Kainate receptors, 881
Amperozide, 125
Amphetamine, 195, 459, 637, 653, 769, 819
Ampicillin, 361
Amygdala, 275
Analgesia, 145, 205
Analog, 295
Angiotensin converting enzyme inhibitor, 751
Angiotensin II, 751
Animal model of depression, 215
 A_9 nerve terminals, 973
Anorexia, 787
Antagonism, 237
Antagonist, 759
Antianalgesia, 331, 623
Antibiotics, 361
Anticonvulsant, 467
Antidepressants, 15, 423
Antiepileptogenic effect, 275
Antinociception, 295, 331
Anxiety, 569, 715, 897, 905, 967
Anxiolytic, 467
Anxiolytic effect, 647
Apomorphine, 135, 283, 587, 769
Appetite, 205
Appetite suppression, 653
Arterial blood pressure, 561
ATPase, 519
Attention, 415, 733
Autoanalgesia, 661
Autoradiography, 251, 631
Bacterial lipopolysaccharide, 787
Behavior, 51, 759, 769, 787, 959, 967
Behavioral activation, 581
Behavioral despair, 225
Behavioral disorganization, 51
Behavioral effects, 161
Behavioral facilitation, 397
Behavioral pharmacology, 435
Behavioral responses, 781
Behavioral stimulation, 553
Behavioural patterns, 709
Benzodiazepine(s), 167, 331, 661
Benzodiazepine receptors, 77, 161
 β_2 adrenergic, 679
 β -Adrenergic antagonists, 131
 β -Adrenergic receptors, 77
 β -Funtrexamine, 813
Binding, 295
Blind humans, 45
Blinded rat pups, 609
Blood alcohol, 365
Blood glucose, 995
Blood pressure, 259
Body temperature, 967
Body weight, 209, 617
Bradykinin, 751
Bradykinin antagonist, 751
Brain, 125, 205
BRL 35135, 953
Bulimia nervosa, 679
Buspirone, 89, 569, 647, 905
 Ca^{2+} channel antagonist, 365
 Ca^{2+} channels, 365
Caffeine, 463, 733
Calcium, 553
Calmodulin, 697, 847
Cannabinoid, 575
Cannabis, 967
Carbohydrate suppression, 349
Carbon clearance test, 605
Carbon monoxide, 259
Castration, 309
Catalepsy, 135, 303
Catecholamine(s), 225, 251
Caudate-putamen, 251
CCK, 237
C57BL/6J mice, 35
CGS 10746B, 989
CGS 19755, 807
Chloramphenicol, 361
Chlordiazepoxide, 467
Chlorpromazine, 467
Chlorpyrifos, 219
Cholera toxin, 623
Cholinergic factors, 911
Cholinesterase, 219
Cholinesterase in RBC and tissues, 827
Chronic ethanol treatment, 27
Chronic treatment, 135
Cigarettes, 259
Circadian, 251
Circadian rhythm, 243, 609
Circadian rhythmicity, 45
 Cl^- influx, 723
Clomipramine, 215
Clonazepam, 995
Clonidine, 39, 111, 265, 623
CNS, 631
Cocaine, 61, 125, 289, 703, 715, 835, 973, 989
Coffee drinking, 527
Cognition, 415, 799
Cognitive deficits, 889
Color and position discrimination, 733
Concurrent acute exercise, 827
Conditional interaction, 467
Conditioned avoidance, 759, 769
Conditioned avoidance responses, 673
Conditioned taste aversion(s), 153, 593
Conditioning, 149
Conflict, 905
Conflict test, 569
Corticosterone, 101
CPP, 807
Culture, 195
(\pm)Cyanopindolol, 349
 D_1 receptor, 51
 D_2 receptor, 51
DA reuptake, 709
DA turnover, 709
[D-Ala²,NMePhe⁴,Gly-ol]Enkephalin, 587
DALDA, 391
DAMGO, 391
d-Amphetamine, 153
Death, 61
d-Fenfluramine, 101, 349
Defensive burying paradigm, 897
Defensive withdrawal paradigm, 897
Delayed matching-to-sample, 733
Delta-9-tetrahydrocannabinol (Δ^9 -THC), 295, 575
[D-Pen³,L-Pen⁵]Enkephalin, 587
(-)-Deprenyl, 709

- Depression, 225, 243, 667
 Desipramine, 89
 Development, 83, 637
 Diazepam; 61, 89, 435, 569, 905
 Diazepam capsule implants, 683
 Diazepam dependence in rats, 683
 Diazepam plasma levels, rats, 683
 Discriminative stimulus effects, 989
 Diurnal, 283
 Dizocilpine, 423
 DOI, 349
 DOM, 459
 Dopamine agonist(s), 51, 269, 703, 769
 Dopamine antagonist, 769
 Dopamine receptor(s), 769, 863
 Dopamine receptor antagonist, 453
 Dopamine uptake sites, 863
 Dopamine, 21, 51, 101, 183, 195, 303, 405, 477, 543, 581, 715, 759, 769, 793, 867, 881, 943, 973
 Dorsal immobility response, 841
 Dorsal striatum (STr), 973
 Dose-response curves, 149
 Drinking, 125, 183
 Drug discrimination, 963
 Drug discrimination learning, 237, 593
 Drug-induced side effects, 739
 Drug-naive and drug-experienced mice, 905
 Drug-taking behavior, 561
 Dynorphin, 623
 Dynorphin A-(1-13), 587
 Dynorphin A(1-17), 331
 Dynorphin antibody, 331
 Dyskinesia, 427
 Dystonia, 427

 8-OH-DPAT, 141, 487
 Elevated plus-maze test, 89
 Enantiomeric forms, 15
 Endogenous dopamine, 819
 Endogenous opioids, 377, 483, 911
 Endopeptidase 24.11, 777
 Endotoxin, 787
 Energy balance, 205, 617
 Energy expenditure, 617
 Energy substrate utilization, 617
 Enkephalinase, 777
 Entrainment, 609
 Ephedrine, 411
 Eserine, 729
 Estradiol, 637, 673
 Estrous cycle, 673
 Ethanol, 35, 283, 309, 477, 519, 535, 661, 781
 Ethanol preference, 853, 857
 Ethological analysis, 67, 873
 Excitatory amino acid, 617
 Exploratory behavior, 101
 Extrapyramidal movement disorders, 793

 Feeding, 487, 917, 967
 Feeding and drinking, 787
 Feeding behavior, 745
 Fenfluramine, 653
 Fentanyl, 315
 Fentanyl induced, 265
 5-HT receptor subtypes, 349
 5-HT receptors, 125
 5-HT_{1A} agonists, 569
 5-HT_{1A} antagonist(s), 67, 873
 5-HT_{1A} receptor(s), 141, 173, 289
 5-HT_{1C} receptor, 289
 5-HT₂ receptor, 289
 5-HT₂ receptor antagonists, 857
 5-HT₃ antagonist, 535
 5-HTergic drugs, 427
 5-Hydroxytryptamine, 487
 Fixed ratio (FR), 667
 Flumazenil, 161, 683
 Flumazenil plasma levels, rats, 683
 Flunarizine, 867
 Fluoxetine, 933
 Flupenthixol, 543
 Food and water intake, 787
 Food consumption, 209
 Food intake, 205, 745, 933
 Food reinforcement, 733
 Forced swim(ming) test, 111, 215, 225
 Formalin, 661
 Foster mother, 609
 Frontal cortex, 323
 Furosemide, 473

 G_i, 623
 GABA, 477
 GABA antagonist, 1
 GABA receptors, 661
 GABA transaminase inhibitor, 1
 GABA_A, 897
 GABA_A benzodiazepine receptor, 723
 GABA_A receptor complex, 963
 GABA_A receptors, 77
 GABA_B receptors, 77
 Gastric fistula, 683
 Gastric transit, 411
 Generalization, 593
 Genetics, 511
 Glutamate, 423
 Glybenclamide, 205
 Glyburide, 205
 Grooming, 51, 673
 Growth rate, 209
 Guanine nucleotide binding or G-protein, 689

 Habituation, 117
 Habituation in the open field, 799
 Haloperidol, 135, 195, 303, 323, 405, 739, 759, 847, 853
 Heart rate, 259
 Hedonic, 745
 Heroin self-administration, 561
 Hexobarbital, 73
 Hibernation, 9
 Hibernation trigger, 9
 Hippocampus, 231, 689
 Histamine, 95
 Histamine H₃ receptor, 95
 Homocysteic acid, 617
 Horizontal movement, 269
 Hormone, 897
 HOT and COLD Mice, 519
 Hot plate, 145
 Hotplate test, 361
 Housing conditions, 723
 HPLC, 303
 [³H]Raclopride, 377
 Human, 927
 Human butyrylcholinesterase (HuBChE), 889
 Human subjects, 781
 Hyperalgesia, 661
 Hyperlocomotion, 535
 Hypermotility, 881

 Hyperphagia, 679
 Hyperthermia, 383
 Hyperthyroidism, 729
 Hypertonic saline intake, 473
 Hypothalamus, 697
 Hypothermia, 283, 309, 519, 729
 Hypoxia, 867

 ICI 118551, 953
 ICS-205,930, 349
 Idazoxan, 215, 265, 933
 Idebenone, 415
 Iloprost, 383
 Imipramine, 423
 Immobility, 295, 647
 Immune system, 787
 Immunity, 445
 Immunomodulator, 787
 Incremental repeated acquisition, 733
 Indirect calorimetry, 617
 Indorenate, 569
 Inescapable stress, 231
 Infection, 787
 Influenza A PR8/34 virus, 167
 Ingestion, 473
 Ingestive behavior, 679
 Inhibition, 219
 Inositol phosphates, 323
 Instrumental behavior, 943
 Interaction, 73
 Interleukin, 787
 Interoceptive cues, 149
 Intracerebroventricular administration, 787
 Intranigral infusion, 427
 Intrathecal naloxone, 331
 Intraventricular, 21
 In vitro, 819
 In vivo electrochemistry (voltammetry), 715, 973
 In vivo protection, 813
 In vivo receptor binding, 377
 Ion transport, 83
 Ipsapirone, 569
 Isoproterenol, 953
 IV, 265

 Kainic acid, 397
 κ, 377
 κ-Opiate receptors, 145
 Ketanserin, 349
 Ketanserin binding, 631
 Kindling, 275

 Learned helplessness, 231, 423
 Learning, 553, 733, 799
 Learning and memory, 959
 Learning behavior, 867
 Levodopa, 195
 Lewis rat, 27
 LHRH, 673
 LHRH antagonism, 673
 Lingual epithelium, 83
 Lithium, 323
 Locomotion, 51
 Locomotor, 703
 Locomotor activity, 95, 111, 135, 295, 341, 391, 587, 637, 989
 Long-term effect, 867
 Long-term potentiation, 847
 Lordosis, 1
 Lower lip retraction, 141
 L-Triiodothyronine, 729

- Macaca mulatta*, 733
 Macrophages, 605
 Magnetic resonance imaging (MRI), 781
 Magnetic resonance spectroscopy (MRS), 781
 Male F344 rat, 101
 Marijuana, 967
 Marmoset, 21
 Mast cell-deficient (*W/W^o*) mouse, 95
 Matching-to-sample, 435
 MDMA, 153, 439
 Meal pattern, 787
 Medial frontal cortex, 101
 Medial prefrontal cortex, 51, 857
 Melatonin, 45, 609
 Memory, 799, 967
 Mental performance, 463
 Menthol, 259
 Metabolism, 205, 617
 Metergoline, 349
 Methamphetamine, 135, 989
 Methionine-enkephalin, 841
 Methionine-enkephalin fragments, 841
 Methylscopolamine, 435
 Mice, 15, 111, 605, 989
 Microdialysis, 341, 477, 581
 Midazolam, 331, 605
 Midbrain raphe nuclei, 487
 MK-801, 15, 881
 Modified forced swim test, 647
 Molecular modeling, 295
 Monoamines, 365, 933
 Mood, 927
 Morphine, 149, 205, 331, 341, 435, 473, 483, 623, 745, 995
 Morris water maze, 889
 Motivation, 581, 733, 943
 Motor activity, 219
 Motor control, 793, 943
 Mouse, 587, 799, 835
 MPTP, 739
 MR 1452, 145
 mRNA, 575
 μ , 377
 μ -Opiate, 519
 μ -Opioid peptide agonists, 391
 Muscarinic receptors, 219
 Muscular rigidity, 265

 N-w-nitro-L-arginine methyl ester, 959
 Naloxone, 117, 145, 473, 917, 995
 Naltrexone, 145, 653
 NAN190, 141
 NBQX, 73
 Neostigmine, 435
 Neostriatum, 943
 Nervous system, 787
 Neural graft, 225
 Neuroimmunology, 787
 Neuroimmunomodulation, 445
 Neuropeptide Y, 543
 Neuroreceptor, 251
 Neurotoxicity, 739
 Nicotine, 131, 135, 209, 283, 303
 Nigrostriatal and mesolimbic DAergic system, 709
 Nigrostriatum, 973
 Nitric oxide, 959
 Nitrous oxide, 161
 Nitrous oxide, 927
 NMDA antagonists, 15
 NMDA receptor, 423, 807

 N-methyl-D-aspartate (NMDA), 959
 Nociception, 205
 Noise, 35
 Nongenomic, 1
 Nonopioid, 117
 Nor-binaltorphimine, 331, 813
 Noradrenaline, 117, 411
 Norepinephrine, 101, 225, 231
 Norpseudoephedrine, 411
 Novelty-induced hypoalgesia, 117
 Nucleus accumbens, 341, 477, 581, 703, 857, 881, 943

 Obese Zucker rats, 653
 Obesity, 617
 Olfactory bulbectomy, 77
 Open-field behavior, 51
 Operant behavior, 581, 733
 Operant chambers, 315
 Operant punishment paradigm, 905
 Opiate(s), 237, 453, 917
 Opiate antagonists, 593
 Opiate or opioid, 689
 Opioid analgesia, 777
 Opioid drugs, 315
 Opioid mediation, 373
 Opioid(s), 117, 183, 473, 745, 819, 917
 Oral movements, 427
 Oral self-administration, 315
 Organophosphate, 219
 Orofacial movements, 405
 Ovariectomy, 673
 Oxotremorine, 729

 Pain, 361, 661
 Palatability, 745, 917
 Panic disorders, 89
 Paraventricular nucleus, 487, 933
 Paraventricular nucleus of the hypothalamus (PVN), 617
 Parkinsonism, 739
 Pattern discrimination, 535
 Pentobarbital, 661
 Pentylentetrazol, 467
 Peptide YY, 679
 Perinatal undernutrition, 89
 Periodic mother deprivation, 609
 Pertussin toxin, 689
 PGE₂, 383
 PGI₂, 383
 Phagocytosis, 605
 Phenelzine, 89
 Phenylpropanolamine, 411
 Phorbol ester binding, 553
 Physostigmine, 435, 827
 Picrotoxin, 661
 Pigeon, 435
 Pindolol, 141
 (-)-Pindolol, 873
 Pineal, 225
 Pineal gland, 45
 Pinobind 5-HT_{1A}, 67
 PL017, 391
 Place conditioning, 543
 Pleasure, 527
 Plus-maze, 467
 Postnatal, 219
 Postsynaptic, 51
 Potentiation, 237
 Prazosin, 61
 Pre- and postweanling rats, 373
 Precipitated abstinence, 683

 Pregnanolone, 897
 Premenstrual syndrome, 897
 Preoptic, 251
 Preoptic area, 39
 Presynaptic, 51
 Pretreatment, 889
 Progesterone, 1, 897
 Prolactin, 101
 Prophylaxis, 889
 Propranolol, 923
 Protection, 889
 Protein kinase C, 553
 Pseudoephedrine, 411
 Psychomotor performance, 927
 Psychomotor stimulant, 453
 Psychostimulant behavior, 715, 973
 Puberty-accelerating pheromone, 835
 Puffing behavior, 527

 Quaternary metabolite, 739
 Quinine, 315
 Quinolinic acid, 303

 Race, 259
 (*R*)- α -Methylhistamine, 95
 Rapid eye movement sleep deprivation, 863
 Rapid smoking, 259
 Rat(s), 21, 45, 51, 73, 117, 131, 141, 161, 209, 243, 251, 309, 383, 415, 427, 473, 483, 569, 617, 751, 787, 819, 863, 889, 897, 959, 989
 Rat brain, 77
 Rat fetus, 377
 Rate of decarbamylation, 827
 Reaction time, 463, 759, 769
 Reactivity, 415
 Rearing, 269
 Receptor, 575, 759, 967
 Recombinant strains, 511
 Rectal temperature, 295
 Reinforcement, 153, 183, 561
 Reinforcer, 927
 REM sleep, 215
 REM sleep deprivation, 111
 Reserpine, 405
 Respiratory arrest, 61
 Respiratory quotient, 617
 Restricted feeding, 609
 Reverse tolerance, 397
 Review, 195
 Reward, 183, 543, 917
 Reward or reinforcement, 689
 Risperidone, 853
 Ritanserin, 349, 853, 857
 Ro 15-1788, 661, 683
 Rockland-Swiss mice, 923
 Rodent, 967
 Rotation-induced analgesia, 911

 S20098, 45
 Saccharin, 483
 Salbutamol, 653
 (*S*)- α -Fluoromethylhistidine, 95
 Salt appetite, 473
 Salt taste, 83
 Sardinian alcohol-preferring rats, 853
 SCH 23390, 759
 Schedule-controlled behavior, 435
 SCN, 251
 Scopolamine, 215, 219, 435
 Screening models, 15
 SDZ 216-525, 873

- Sedation, 967
 Seizures, 61, 365, 467
 Selected lines, 519
 Self-administration, 125, 689
 Self-stimulation, 453
 Sensitization, 341
 Septum, 251
 Serotonin, 9, 21, 101, 125, 225, 289, 365, 477, 569, 715, 923, 973
 Serotonin *N*-acetyltransferase rhythm, 609
 Serotonin-2 receptors, 631
 7-Chlorokynurenic acid, 275
 Sex and age differences, 985
 Sex differences, 637, 777
 Sexual behavior, 1, 215
 Sexual conduct, 697
 Sexual differentiation, 637
 Shock intensity, 569
 Short-term memory, 733
 6-Hydroxydopamine, 397
 SK&F38393, 269
 SK&F77434, 269
 SK&F82958, 269
 Skinner box, 667
 Sleep disorders, 45
 Sleeping time, 73
 SM-3997, 647
 Smoking, 527
 Social behavior, 67, 873
 Social interaction, 161
 Soman, 889
 Spatial learning, 27, 415
 Spiperone, 759
 Stearate microelectrode, 973
 Stereotyped behavior, 135
 Stereotypic behavior, 51
 Stereotypy, 637
 Stereotypy behavior, 269
 Steroid, 1
 Straw suspension, 647
 Straw-climbing behavior, 647
 Stress, 35, 101, 167, 315, 445, 511, 605
 Stress-induced analgesia, 777
 Stress-induced antinociception, 373
 Striatum, 195, 303, 323, 341, 819, 863, 867
 Structure-activity relationship, 295
 Strychnine-insensitive glycine receptors, 275
 Subcellular distribution, 553
 Subjective effects, 927
 Substantia nigra, 427
 Supersensitivity, 397
 Suprachiasmatic, 251
 Swimming activity, 111
 Tail electric stimulation test, 373
 Tail-flick, 149
 Tail-tremor, 131
 Tardive dyskinesia, 739
 Target biting, 923
 Taste, 745
 Temperature, 483, 953
 Temporal discrimination learning, 27
 Temporal response differentiation, 733
 Terbutaline, 679
 Testosterone, 637, 835
 Thermal balance, 953
 Thermogenesis, 617
 Thermoregulatory behavior, 953
 Thigmotaxis, 269
 Thiocetic acid, 799
 Thirst, 39
 3 α ,5 α -Tetrahydroprogesterone, 897
 Thyroid, 243, 251
 Thyroparathyroidectomy, 243, 251
 Thyroxine, 243, 251
 Time estimation, 733
 Titration schedule, 435
 Tolerance, 149, 283, 309, 341
 Tourette's syndrome, 303
 Transduction, 83
 Tremor, 729
 Trophic factor, 195
 Tryptophan hydroxylase, 9
 U 50-488, 145
 Unpredictable electric shock, 667
 Vacuous jaw movements, 793
 Valproate, 323
 Variable ratio, (VR), 667
 Vasopressin, 309
 Ventral tegmental area, 689, 857
 Ventrolateral nucleus accumbens (vlnAcc), 715
 Ventromedial hypothalamus (VMH), 251
 Vervet monkeys, 985
 Vestibular compensation, 807
 Virus infection, 167
 Water consumption, 209
 Water deprivation, 315
 Water intake, 39
 Weight cycling, 209
 Weight loss, 653
 Withdrawal, 897
 Xylamidine, 349
 Yohimbine, 111
 Zymosan test, 605

PHARMACOLOGY BIOCHEMISTRY & BEHAVIOR

VOLUME 46 1993

AUTHOR INDEX

- Abbott, F. V., 661
Ablordeppey, S. Y., 739
Abood, M. E., 575
Ágmo, A., 183
Aguilar-García, A., 215
Akarsu, E. S., 383
Albertson, T. E., 61
Allen, R. R., 733
Almeida, O. M. S., 729
Altenbaumer, M., 15
Alvares, K., 315
Amit, Z., 179
Andersen, S. L., 377
Andrén, P. E., 427
Anisman, H., 445, 511
Araki, Y., 131, 135
Armstrong, S. M., 45
Arts, K. S., 623
Asakura, W., 111
Ashani, Y., 889
Atrens, D. M., 153, 617
Axelrod, J., 967
Ayhan, I. H., 383
- Babu, S. R., 827
Baeza, R., 673
Balboa, J. L., 167, 605
Bardo, M. T., 819
Baskin, P., 793
Bättig, K., 463, 527
Beauchemin, V., 77
Bell, R., 67, 873
Belmonte, A., 167, 605
Benavente, F., 673
Beninger, R. J., 543
Bergsträsser, E., 867
Berndt, C., 867
Berridge, K. C., 745
Bianchi, M., 145
Billington, C. J., 917
Björk, A., 125
Blokland, A., 27
Blundell, J. E., 349
Borkoski, J. P., 787
Borne, R. F., 739
Bowers, R. L., 483
Boyd, N. E., 205
Boyle, A. E., 179
Brandeis, R., 889
Braun, A. R., 51
Brock, J., 863
Broderick, P. A., 715, 973
Bryson, R., 35
Buffalo, E. A., 733
Buhriend, C. M., 195
Bunge, A., 463
Burgess, L. H., 101
Cabrera, T. M., 101
- Cañill, D. W., 303
Callera, J. C., 39
Camargo, L. A. A., 39
Campbell, D. B., 101
Campos, M. F., 21
Canchola, E., 697
Carlisle, H. J., 953
Carver, P. M., 195
Caskey, N. H., 259
Cepeda-Benito, A., 149
Chae, Y.-L., 231
Chait, A., 361
Chakraborti, T. K., 219
Charalambous, A., 295
Chen, C.-J., 835
Chernet, E., 631
Chiu, T.-M., 781
Christie, M. J., 153
Cicala, G. A., 959
Ciccocioppo, R., 853, 857
Cimetiere, C., 361
Clor, K. M., 995
Coalson, D. W., 927
Cohen, E., 889
Cohen, S. A., 799
Coleman, C., 35
Compton, D. R., 295
Cordoba, N. E., 89
Corwin, R. L., 967
Coscina, D. V., 487
Cousins, M. S., 581, 943
Crain, S. M., 623
Crawley, J. N., 967
Cross, M. K., 101
Cullen, M. J., 415
Cumin, R., 905
Curtis, B. A., 161
Czech, D. A., 161
- Dal Prá, G., 463
Dal Prá, P., 423
Dall, V., 73
Darlington, C. L., 807
Dawes, P., 117
de Beaurepaire, R., 361
De Cabo, C., 373
De Luca, L. A., Jr., 39
De Montis, M. G., 423
De Witte, P., 477
Dean, J. E., 209
DeBold, J. F., 1
Del Vecchio, R. A., 265
Dennis, T., 77
Derlet, R. W., 61
Deutsch, S. I., 963
Devane, W. A., 967
Díaz-Ruiz, O., 215
- Díaz-Vélez, G., 673
Dobrosielski, M., 781
Dohrn, C. S., 927
Dorow, J., 519
Doyle, T. G., 745
Drucker, G. E., 195
Dube, S. N., 827
Dubuc, P. U., 953
Dussaubat, N., 673
- El-Etri, M. M., 303
Emerich, D. F., 303
Eng, F., 715
Ervin, F. R., 985
Estall, L. B., 959
- Falb, D. C., 483
Fan, F., 575
Farrar, J. D., 219
Federman, I., 183
Felder, C. C., 967
Feller, D. J., 519
Fernandez-Rial, J. C., 167
Fields, J. Z., 195
Fiorella, D., 289
Fischer, H. D., 867
Fitzgerald, A. L., 911
Flemming, D., 927
Fletcher, P. J., 487
Forgie, M. L., 637
Franklin, K. B. J., 661
Freire-Garabal, M., 167, 605
French, D., 989
Frye, C. A., 1
Fujimoto, J. M., 331, 623
Fukushima, T., 847
Furuno, K., 131, 135
- Gallo, M. A., 897
Gambarana, C., 423
George, M., 101
Gillam, M. P., 733
Giraud, S. Q., 917
Glennon, R. A., 459
Glick, S. D., 341
Gomita, Y., 131, 135
Gondoh, Y., 647
González-Bahillo, J., 605
Gordon, B. H., 101
Gosnell, B. A., 745
Grace, M. K., 917
Grady, D. R., 365
Grant, S. J., 959
Grigdesby, C. F., 911
Gross, J., 867
Gross, T. M., 259
Grunberg, N. E., 315
Grunwald, J., 889
- Grupp, L. A., 751
Grzybowska, J., 295
Guardiola-Lemaitre, B., 45
Gunne, L. M., 427
Guzman-Flores, C., 985
Gyarmati, S., 709
- Haefely, W., 553
Hagan, M. M., 679
Hamdi, A., 863
Hampe, S., 15
Handa, R. J., 101
Hara, C., 667
Harding, S., 751
Hársing, G. L., 709
Hartmann, H., 799
Hasenfratz, M., 463, 527
Hata, N., 101
Heidbreder, C., 477
Hill, L. J., 125
Hobson, H., 67, 873
Hodges, B. L., 161
Holtzman, S. G., 813
Hong, E., 569
Hubbell, C. L., 473
Hudzik, T. J., 435
Hull, K. M., 411
Huston-Lyons, D., 453
- Innes, D. G. L., 777
- Jackson, D. M., 153
Jacobson, A., 527
Janowsky, D., 365
Jarvik, M. E., 259
Jaskiw, G. E., 51
Jenck, F., 905
Jibiki, I., 847
Johnson, A. E., 427
Johnson, D. W., 341
Johnson, R. G., 289
Jones, E. A., 125
Josselyn, S. A., 543
Juarez, J., 985
- Kaddis, F. G., 703
Kameyama, T., 587
Kato, Y., 609
Kavaliers, M., 777
Kehoe, P., 377
Kirch, D. G., 323
Kiyatkin, E. A., 561
Klein, L. C., 315
Klug, J. M., 397
Knoll, J., 709
Kolachana, B. S., 51
Kolta, M. G., 819
Kornak, E. P., Jr., 715

- Kornetsky, C., 453
 Kramer, G., 231
 Kubota, T., 847
 Kulikov, A. V., 9
 Kurokawa, K., 847
- Laino, C. H., 89
 Lauchlan, C. L., 243
 Lavoie, N., 77
 Lawton, C. L., 349
 Leibowitz, S. F., 933
 Levine, A. S., 917
 Li, R., 323
 Li, T.-K., 173, 631, 723
 Lichtor, J. L., 927
 Liminga, U., 427
 Lin, D., 195
 Lin, H. Q., 153
 Lin, S., 295
 Lo, E. S., 195
 Lorens, S. A., 101
 Lukas, S. E., 781
 Lumeng, L., 173, 631, 723
 Lun, A., 867
- Maeyama, K., 95
 Maher, T. J., 411
 Maickel, R. P., 911
 Maillefer, R. H., 161
 Makryiannis, A., 295
 Marciniak, G., 295
 Martin, B. R., 295, 575
 Martin, J. R., 553, 905
 Martin, M. I., 373
 Martin, W. R., 683
 Massi, M., 853, 857
 Mastropalo, J., 963
 Matray-Devoti, J., 923
 Matsumoto, K., 111
 Mayfield, R. D., 759, 769
 McBride, W. J., 631, 723
 McCarthy, W. J., 259
 McCullough, L. D., 581
 McCutcheon, N. B., 473
 McEachron, D. L., 243, 251
 McGivern, R. F., 309
 McGonigle, P., 251
 McGregor, I. S., 153
 McMillen, B. A., 125
 McNulty, O. M., 45
 Melcer, T., 309
 Melchior, C. L., 309
 Meloni, D., 423
 Melton, P. M., 237
 Menani, J. V., 39
 Mendelson, J. H., 781
 Menéndez, J. A., 617
 Meneses, A., 569
 Mermelstein, P. G., 1
 Meyer, Melissa E., 391
 Meyer, Merle E., 269, 391, 841
 Midgley, D. E., 243
 Mierson, S., 83
 Mizinga, K. M., 283
 Mollnauer, S., 35
 Molthen, R. C., 251
 Moore, N. A., 141
- Mora, S., 673
 Moreau, J.-L., 905
 Morimoto, K., 275
 Moss, D. E., 679
 Müller, W. E., 799
 Myers, R. D., 125
- Najim, R. A., 995
 Namba, T., 275
 Nārāyaṇan, S., 881
 Naruo, T., 667
 Navarro, V., 183
 Newcastle, L. D., 483
 Nishimura, H., 647
 Nordholm, L., 73
 Norman, A. B., 303, 397
 Nozoe, S.-I., 667
 Núñez, M. J., 167, 605
- O'Brien, R. A., 365
 Ogawa, N., 667
 Ohta, H., 111
 Oliveira, M. P., 21
 Onödéra, K., 95
 Ørntoft, U., 73
 Orsinger, O. A., 89
 Otsuki, S., 275
- Padua, M., 183
 Paez, X., 933
 Palmour, R. M., 985
 Panconi, E., 15
 Panerai, A. E., 145
 Panocka, I., 853, 857
 Paronis, C. A., 813
 Paule, M. G., 733
 Pellemounter, M. A., 415
 Perrett, L., 141
 Petty, F., 231
 Plata-Salamán, C. R., 787
 Polidori, C., 857
 Pompei, P., 853
 Pope, C. N., 219
 Popova, N. K., 9
 Porsolt, R. D., 15
 Pournaghash, S., 593
 Prasad, C., 863
 Prickaerts, J., 27
 Ptak, L. R., 195
 Pucilowski, O., 365
 Pujol, A., 373
- Quock, R. M., 161
- Raaijmakers, W., 27
 Rabin, R. A., 289
 Rabold, J. A., 631
 Rady, J. J., 331
 Rajachandran, L., 535
 Randall, P. K., 759, 769
 Raveh, L., 889
 Redman, J. R., 45
 Rees, G., 141
 Reid, L. R., 173
 Renzi, A., 39
 Rezvani, A. H., 365
 Riley, A. L., 237, 593
- Roane, D. S., 205
 Robertson, J. M., 751
 Robinson, J. K., 967
 Robinson, S. R., 377
 Robison, M., 35
 Röchford, J., 117
 Rodríguez-Medina, M., 697
 Rosado, A., 697
 Rosenblatt, M. R., 259
 Ross, K., 863
 Roux, J., 15
 Rushing, P. A., 209
- Saad, W. A., 39
 Sagen, J., 225
 Sakai, N., 95
 Salamone, J., 793
 Salamone, J. D., 405, 581, 943
 Sanberg, P. R., 303
 Sanger, G., 141
 Sansom, A. J., 807
 Santos, R., 729
 Sardo, J., 35
 Sarkar, M., 453
 Saus, C., 575
 Scheller, D., 867
 Schmidt, A., 73
 Schoch, P., 553
 Segal, R., 179
 Self, D. W., 689
 Semus, S. F., 295
 Settles, A. M., 83
 Sexton, R. H., 51
 Shāhānī, Y., 315
 Shanks, N., 511
 Shaw, W. N., 653
 Shipley, M. T., 303
 Shults, J. M., 269
 Sloan, J. W., 683
 Smith, B. R., 179
 Smith, P. F., 807
 Smith, S. S., 897
 Smotherman, W. P., 377
 Sokolowski, J. D., 943
 Soliman, K. F. A., 283
 Somani, S. M., 827
 Sortwell, C. E., 225
 Spear, L. P., 535
 Spear, N. E., 535
 Spieler, K., 553
 Spirduso, W. W., 759, 769
 Sprague, J. E., 911
 Stein, E. A., 361
 Stein, L., 689
 Steinpreis, R. E., 405
 Stewart, J., 637
 Stock, M. J., 953
 Stoll, S., 799
 Stuart, J. F., 519
 Suaudeau, C., 361
 Suckow, M. A., 911
 Suemaru, K., 131, 135
 Sugishita, M., 609
- Taddei, I., 423
 Tagliamonte, A., 423
 Takahashi, K., 609
- Takashima, M., 609
 Takeuchi, Y., 609
 Tanaka, H., 667
 Tanaka, M., 647
 Taukulis, H. K., 467
 Tekes, K., 709
 Teoh, S. K., 781
 Thielen, R. J., 723
 Tiffany, S. T., 149
 Tilton, C. L., 575
 Timár, J., 709
 Toyoshi, T., 587
 Tseng, C.-C., 61
 Tsuda, A., 647
- Uetrecht, R. L., 911
 Ukai, M., 587
 Umphress, S. M., 377
 Uretsky, N. J., 703, 881
 Urresta, F., 673
- Vandenberg, J. G., 835
 Velazquez, G., 183
 Velazquez-Moctezuma, J., 215
 Vergara-Onofre, M., 697
 Vessotskie, J. M., 251
 Viveros, M. P., 373
 Vladar, K., 51
 Voronova, I. P., 9
- Waddell, A. B., 813
 Wagner, G. C., 923
 Wakita, S., 847
 Wala, E. P., 683
 Wallace, L. J., 703, 881
 Ward, K. M., 377
 Watanabe, H., 111
 Watanabe, T., 95
 Wechsler, R., 715
 Weinberger, D. R., 51
 Welch, C. C., 917
 Wenger, G. R., 435
 Wetzel, P. J., 161
 Wilcox, R. E., 759, 769
 Wilkins, D. R., II, 209
 Williams, H. L., 125
 Williams, R. L., 283
 Willins, D. L., 881
 Wilson, L., 231
 Winders, S. E., 209
 Wing, L. L., 323
 Witkin, J. M., 989
 Wong, D. T., 173
 Woods, B. T., 781
 Wright, D. W., 435
 Wyatt, R. J., 323
- Yamada, N., 275
 Yamaguchi, N., 847
 Yamauchi, T., 609
 Yamazaki, S., 95
 Yanai, K., 95
- Zacny, J. P., 927
 Zalzman, S., 445
 Zanol, M. D., 303
 Zanzillari, R., 411